Content

Intangible Assets: The Royal Opportunity Set

In this Q&A, Jon Rotolo, Barings’ Head of Private Equity / Real Assets, and David Jin, a Director within the Private Equity / Real Assets group, discuss why they believe pharmaceutical royalties present a particularly compelling investment opportunity.

This is premium content

You are not logged in, Sign in or register to request access.
Please note: If you had prior access to this content you may need to sign in again.

Asset Owners

If you are an institutional investor you are eligable for free access to all premium content.

Asset Managers

Asset managers with enhanced profiles are eligable for full access.

Please sign-in using your work email address or:

Barings

Intangible Assets: The Royal Opportunity Set

This is premium content

Asset Owners

Asset Managers

Barings

Related categories